Farnesylated RhoB inhibits radiation-induced mitotic cell death and controls radiation-induced centrosome overduplication

Cell Death and Differentiation

Volumn 12, Issue 5, 2005, Pages 492-501

  Milia, J ^a   Teyssier, F ^a   Dalenc, F ^a   Ader, I ^a   Delmas, C ^a   Pradines, A ^a   Lajoie Mazenc, I ^a   Baron, R ^a   Bonnet, J ^a   Cohen Jonathan, E ^a   Favre, G ^a   Toulas, C ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Centrosome duplication; Ionizing radiation; Mitotic cell death; Radioresistance; Rho B

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RHO FACTOR; TIPIFARNIB;

ARTICLE; CELL CULTURE; CELL CYCLE G2 PHASE; CELL DEATH; CELL STRAIN 3T3; CELL SURVIVAL; CENTROSOME; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOPRECIPITATION; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION EXPOSURE; RADIOSENSITIVITY; STUDENT T TEST; WESTERN BLOTTING;

EID: 20844438204     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401586     Document Type: Article

References (43)

1. Dikomey E, Borgmann K, Brammer I and Kasten-Pisula U (2003) Molecular mechanisms of individual radiosensitivity studied in normal diploid human fibroblasts. Toxicology 193: 125-135
2. Jonathan EC, Bernhard EJ and McKenna WG (1999) How does radiation kill cells? Curr. Opin. Chem. Biol. 3: 77-83
3. Tounekti O, Pron G, Belehradek Jr J and Mir LM (1993) Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res. 53: 5462-5469
4. Lock RB and Stribinskiene L (1996) Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res. 56: 4006-4012
5. Torres K and Horwitz SB (1998) Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res. 58: 3620-3626
6. Cohen-Jonathan E, Toulas C, Ader I, Monteil S, Allal C, Bonnet J, Hamilton AD, Sebti SM, Daly-Schveitzer N and Favre G (1999) The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS. Radiat Res. 152: 404-411
7. Delmas C, Heliez C, Cohen-Jonathan E, End D, Bonnet J, Favre G and Toulas C (2002) Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int. J. Cancer 100: 43-48
8. Roninson IB, Broude EV and Chang BD (2001) If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist. Update 4: 303-313
9. Sato N, Mizumoto K, Nakamura M, Ueno H, Minamishima YA, Farber JL and Tanaka M (2000) A possible role for centrosome overduplication in radiation-induced cell death. Oncogene 19: 5281-5290
10. Sato N, Mizumoto K, Nakamura M and Tanaka M (2000) Radiation-induced centrosome overduplication and multiple mitotic spindles in human tumor cells. Exp. Cell. Res. 255: 321-326
11. Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ and McKenna WG (1996) The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res. 56: 1727-1730
12. Bernhard EJ, McKenna WG, Hamilton AD, Sebti SM, Qian Y, Wu JM and Muschel RJ (1998) Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res. 58: 1754-1761
13. Lebowitz PF and Prendergast GC (1998) Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene 17: 1439-1445
14. Van Aelst L and D'Souza-Schorey C (1997) Rho GTPases and signaling networks. Genes Dev. 11: 2295-2322
15. Fritz G, Kaina B and Aktories K (1995) The ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments. J. Biol. Chem. 270: 25172-25177
16. Adamson P, Marshall CJ, Hall A and Tilbrook PA (1992) Post-translational modifications of p21rho proteins. J. Biol. Chem. 267: 20033-20038
17. Baron R, Fourcade E, Lajoie-Mazenc I, Allal C, Couderc B, Barbaras R, Favre G, Faye JC and Pradines A (2000) RhoB prenylation is driven by the three carboxyl-terminal amino acids of the protein: evidenced in vivo by an anti-farnesyl cysteine antibody. Proc. Natl. Acad. Sci. USA 97: 11626-11631
18. Liu A and Prendergast GC (2000) Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors. FEBS Lett. 481: 205-208
19. Liu A, Cerniglia GJ, Bernhard EJ and Prendergast GC (2001) RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. Proc. Natl. Acad. Sci. USA 98: 6192-6197
20. Chen Z, Sun J, Pradines A, Favre G, Adnane J and Sebti SM (2000) Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J. Biol. Chem. 275: 17974-17978
21. Ader I, Toulas C, Dalenc F, Delmas C, Bonnet J, Cohen-Jonathan E and Favre G (2002) RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death. Oncogene 21: 5998-6006
22. Ader I, Delmas C, Bonnet J, Rochaix F, Favre G, Toulas C and Cohen-Jonathan-Moyal E (2003) Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts. Oncogene 22: 8861-8869
23. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud F, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W and Bowden C (2001) Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 61: 131-137
24. Allal C, Pradines A, Hamilton AD, Sebti SM and Favre G (2002) Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298. Cell Cycle 1: 430-437
25. Lajoie-Mazenc I, Tollon Y, Detraves C, Julian M, Moisand A, Gueth-Hallonet C, Debec A, Salles-Passador I, Fuget A, Mazarguil H, Raynaud-Messina B and Wright M (1994) Recruitment of antigenic gamma-tubulin during mitosis in animal cells: presence of gamma-tubulin in the mitotic spindle. J. Cell. Sci. 107 (Part 10): 2825-2837
26. Hwang A and Muschel RJ (1998) Radiation and the G2 phase of the cell cycle. Radiat. Res. 150: 552-559
27. Maity A, Kao GD, Muschel RJ and McKenna WG (1997) Potential molecular targets for manipulating the radiation response. Int. J. Radiat. Oncol. Biol. Phys. 37: 639-653
28. Wherlock M, Gampel A, Futter C and Mellor H (2004) Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase. J. Cell. Sci. 117: 3221-3231
29. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, Nakano T, Okawa K, Iwamatsu A and Kaibuchi K (1996) Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 15: 2208-2216
30. Inada H, Togashi H, Nakamura Y, Kaibuchi K, Nagata K and Inagaki M (1999) Balance between activities of Rho kinase and type 1 protein phosphatase modulates turnover of phosphorylation and dynamics of desmin/vimentin filaments. J. Biol. Chem. 274: 34932-34939
31. Chevrier V, Piel M, Collomb N, Saoudi Y, Frank R, Paintrand M, Narumiya S, Bornens M and Job D (2002) The Rho-associated protein kinase p160ROCK is required for centrosome positioning. J. Cell Biol. 157: 807-817
32. Ishizaki T, Uehata M, Tamechika I, Keel J, Nonomura K, Maekawa M and Narumiya S (2000) Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol. Pharmacol. 57: 976-983
33. Strunz AM, Peschke F, Waldeck W, Ehemann V, Kissel M and Debus J (2002) Preferential radiosensitization in p53-mutated human tumour cell lines by pentoxifylline-mediated disruption of the G2/M checkpoint control. Int. J. Radiat. Biol. 78: 721-732
34. Geldof AA, Plaizier MA, Duivenvoorden I, Ringelberg M, Versteegh RT, Newling DW and Teule GJ (2003) Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line. J. Cancer Res. Clin. Oncol. 129: 175-182
35. Lange BM (2002) Integration of the centrosome in cell cycle control, stress response and signal transduction pathways. Curr. Opin. Cell Biol. 14: 35-43
36. Pihan GA, Purohit A, Wallace J, Malhotra R, Liotta L and Doxsey SJ (2001) Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res. 61: 2212-2219
37. Pihan GA, Wallace J, Zhou Y and Doxsey SJ (2003) Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res. 63: 1398-1404
38. Pihan GA, Purohit A, Wallace J, Knecht H, Woda B, Quesenberry P and Doxsey SJ (1998) Centrosome defects and genetic instability in malignant tumors. Cancer Res. 58: 3974-3985
39. Cahill DP, Kinzler KW, Vogelstein B and Lengauer C (1999) Genetic instability and darwinian selection in tumours. Trends Cell Biol. 9: M57-M60
40. Dodson H, Bourke E, Jeffers LJ, Vagnarelli P, Sonoda E, Takeda S, Earnshaw WC, Merdes A and Morrison C (2004) Centrosome amplification induced by DNA damage occurs during a prolonged G2 phase and involves ATM. EMBO J. 23: 3864-3873
41. Brinkley BR (2001) Managing the centrosome numbers game: from chaos to stability in cancer cell division. Trends Cell Biol. 11: 18-21
42. Du J and Hannon GJ (2004) Suppression of p160ROCK bypasses cell cycle arrest after Aurora-A/STK15 depletion. Proc. Natl. Acad. Sci. USA 101: 8975-8980
43. Riento K and Ridley AJ (2003) Rocks: multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell. Biol. 4: 446-456